Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13338853 | 0.83 | SIGMAR1 (0.43) | SIGMAR1GAACYP1A2CYP2D6SLC6A2 | |
| SCHEMBL14069675 | 0.83 | SIGMAR1 (0.43) | SIGMAR1GAACYP1A2CYP2D6SLC6A2 | |
| SCHEMBL21348037 | 0.83 | SIGMAR1 (0.43) | SIGMAR1GAACYP1A2CYP2D6SLC6A2 | |
| SCHEMBL20629037 | 0.81 | SIGMAR1 (0.49) | SIGMAR1CYP1A2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL15399896 | 0.81 | SIGMAR1 (0.53) | SIGMAR1CYP1A2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL29553747 | 0.81 | SIGMAR1 (0.53) | SIGMAR1CYP1A2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL13338895 | 0.81 | SIGMAR1 (0.44) | SIGMAR1GAACYP1A2CYP2D6SLC6A2 | |
| SCHEMBL759961 | 0.79 | SIGMAR1 (0.40) | SIGMAR1GAACYP1A2CYP2D6SLC6A2 | |
| SCHEMBL13339019 | 0.79 | SIGMAR1 (0.40) | SIGMAR1GAACYP1A2CYP2D6SLC6A2 | |
| SCHEMBL17693516 | 0.79 | SIGMAR1 (0.40) | SIGMAR1GAACYP1A2CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148666-A1 | DINITROXIDE BIRADICAL COMPOUNDS AS POLARIZING AGENTS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148666-A1 | DINITROXIDE BIRADICAL COMPOUNDS AS POLARIZING AGENTS | NDC1, NUCB2, MDM4 | SIGMAR1 1398/4885GAA 2894/4885CYP1A2 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.